David S. Grayzel

This profile gathers the share dealings of David S. Grayzel across 2 companies, led by Surface Oncology, Inc. and Jade Biosciences, Inc. Between 23 April 2018 and 9 April 2024, the trades on record add up to 8 filings.

On the open market, the record shows 2 purchases worth €7.6M and 3 sales worth €36.8M. Netting one side against the other leaves €29.3M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. 2024 to date brings no purchases and 1 sale.

The newest entry dates from 11 April 2024: an open-market sale of €308k, in Jade Biosciences, Inc. The latest purchase dates back some time: it was published 1,935 days ago, on 6 July 2021. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.